Ensysce Biosciences selects lead drug candidate (PF9001) for opioid use disorder with improved safety and abuse deterrence.
Ensysce Biosciences, a clinical-stage pharmaceutical firm, has selected a lead drug candidate (PF9001) with abuse deterrence and improved safety for opioid use disorder (OUD). The candidate, developed using Ensysce's TAAP platform, has lower potential for cardiovascular side effects compared to traditional methadone OUD treatments. This milestone was achieved with support from a $15M multi-year HEAL award from the NIH and NIDA.
June 06, 2024
4 Articles